ꀅ EN

Beyond mutations.

Towards functional precision.


Unlocking therapeutic targets with patient-derived organoids and high-throughput functional genomics.

ꂃ ꁹ

New Drug Research and Development

Comprehensive Organoid Biobank

 

•  Provides diverse disease models to support drug discovery
•  The company has completed the modeling of more than 1500              human tumor organs, involving various tumor organoids.
•  Established a complete set of self-sampling, culture,                             cryopreservation, passage, drug sensitivity testing, flow cytometry       testing, inspection reports and other enterprise standards.

PDO-TRiC in situ Target Capture

Leveraging advanced functional genomics for precision target discovery and validation
•  Using animal in situ, 3D organoid models
•  Independent research and development of student                letter/AI/statistical algorithm analysis
•  Huge advantages over traditional 2D cell culture                   screening

High-throughput Drug Sensitivity Screening

 

Rapid assessment of drug response across models.
High-throughput, multi-dimensional drug sensitivity evaluation can not only efficiently screen tumor-targeted drugs, but also evaluate the response of different treatment options (such as chemotherapy, targeted therapy, immunotherapy) to individual tumors, greatly improving the clinical consistency and conversion rate of drug screening results.

Mechanism of Action and Target Validation

 

Employing a multi-dimensional validation strategy to confirm therapeutic targets

Drug Efficacy and Toxicity

 

Accurate assessment of therapeutic potential and safety.